EcoDrugPlus

Complement C5

Ensembl ID : ENSBTAG00000012210
Gene Symbol: C5
13 Enzyme and pathways 5 Cross references
224 Possible Orthologues:

Complement Factor D

Ensembl ID : ENSBTAG00000048122
Gene Symbol: CFD
10 Enzyme and pathways 5 Cross references
145 Possible Orthologues:

Cyclin D1

Ensembl ID : ENSBTAG00000017514
Gene Symbol: CCND1
27 Enzyme and pathways 5 Cross references
286 Possible Orthologues:

Cyclin Dependent Kinase 1

Ensembl ID : ENSBTAG00000010109
Gene Symbol: CDK1
64 Enzyme and pathways 5 Cross references
257 Possible Orthologues:

Cyclin Dependent Kinase 2

Ensembl ID : ENSBTAG00000004021
Gene Symbol: CDK2
60 Enzyme and pathways 5 Cross references
212 Possible Orthologues:

Cyclin Dependent Kinase 4

Ensembl ID : ENSBTAG00000007160
Gene Symbol: CDK4
29 Enzyme and pathways 4 Cross references
243 Possible Orthologues:

Cyclin Dependent Kinase 5

Ensembl ID : ENSBTAG00000007766
Gene Symbol: CDK5
17 Enzyme and pathways 5 Cross references
174 Possible Orthologues:

Cyclin Dependent Kinase 6

Ensembl ID : ENSBTAG00000044023
Gene Symbol: CDK6
17 Enzyme and pathways 5 Cross references
213 Possible Orthologues:

Cyclin Dependent Kinase 7

Ensembl ID : ENSBTAG00000011046
Gene Symbol: CDK7
43 Enzyme and pathways 5 Cross references
231 Possible Orthologues:

Cyclin Dependent Kinase 9

Ensembl ID : ENSBTAG00000004695
Gene Symbol: CDK9
17 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Cysteinyl Leukotriene Receptor 1

Ensembl ID : ENSBTAG00000024675
Gene Symbol: CYSLTR1
8 Enzyme and pathways 5 Cross references
193 Possible Orthologues:

Cytidine Deaminase

Ensembl ID : ENSBTAG00000052516
Gene Symbol: CDA
7 Enzyme and pathways 5 Cross references
239 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).